Moderna Inc. told investors today that is intends to soon file for full Food and Drug Administration approval for its COVID-19 vaccine. Moderna, whose vaccine was authorized for emergency use in December for individuals age 18 and older, said its trial data shows that its vaccine is 96% effective in 12 to 17 year-olds who received at least one injection.  

Moderna yesterday announced that its vaccine booster, which remains in a phase 2 clinical trial, showed positive immune response for several COVID-19 variants, including those first discovered in South Africa and Brazil. The booster is intended for administration in patients who already completed the standard, two-dose regimen.

 

Related News Articles

Headline
The Department of Health and Human Services today announced a $3 billion investment in antiviral treatments for COVID-19, particularly those administered…
Headline
The Centers for Disease Control and Prevention June 11 updated requirements for health care providers participating in the COVID-19 Vaccination Program to…
Headline
The Food and Drug Administration yesterday authorized for emergency use one more batch of drug substance manufactured for the Janssen (Johnson &…
Headline
Rhode Island health care providers may no longer order the monoclonal antibodies bamlanivimab and etesevimab until further notice due to rising prevalence of…
Headline
Moderna Inc. today announced an agreement with the U.S. government for the purchase of an additional 200 million doses of Moderna’s COVID-19 vaccine,…
Headline
Only 11% of pregnant women in the Centers for Disease Control and Prevention’s Vaccine Safety Datalink, which includes vaccine safety monitoring data from nine…